This inventor holds 2 USPTO granted patents. Top assignee: Gigamune, Inc.. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: Ayla Lynn Nelson: Innovator in Viral Therapeutics
Introduction
Ayla Lynn Nelson is a prominent inventor based in San Francisco, California. She has made significant contributions to the field of viral therapeutics, particularly through her innovative research and development of engineered cells.
Latest Patents
Ayla holds a patent for "Engineered cells expressing anti-viral T cell receptors and methods of use thereof." This patent includes compositions comprising recombinant mammalian cells that express recombinant T cell receptors with specificity against EBV or CMV peptide:MHC antigens. Additionally, it outlines therapeutic methods for using these recombinant mammalian cells as cell therapies against viral infections.
Career Highlights
Ayla is currently associated with Gigamune, Inc., where she continues to advance her research in the field of immunotherapy. Her work focuses on developing novel approaches to combat viral infections, showcasing her dedication to improving health outcomes.
Collaborations
Ayla collaborates with notable colleagues, including Matthew James Spindler and David Scott Johnson, who contribute to her research efforts and the advancement of their shared goals in viral therapeutics.
Conclusion
Ayla Lynn Nelson is a trailblazer in the field of engineered cell therapies, with her innovative patent paving the way for new treatments against viral infections. Her work exemplifies the impact of dedicated research and collaboration in advancing medical science.